Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363893 · ClinicalTrials.gov registry record · Phase 1
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
A Phase 1 study, sponsored by Carrick Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
NCT03363893 is a Phase 1 study that has completed, run by Carrick Therapeutics Limited. The registered enrollment target is 124 participants.
The verdict
NCT03363893, a Phase 1 study, has completed, sponsored by Carrick Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.
Interventions
- DRUG Fulvestrant
- DRUG CT7001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03363893
The ClinicalTrials.gov registry entry for NCT03363893 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carrick Therapeutics Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT03363893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03363893 about?
NCT03363893 is a clinical study titled "Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies". This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Pros...
What is the current status of trial NCT03363893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2017-11-14. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT03363893?
The interventions under investigation include: Fulvestrant (DRUG), CT7001 (DRUG).
Who is sponsoring clinical trial NCT03363893?
This trial is sponsored by Carrick Therapeutics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.